Nearly Pain-Free Self-administration of Subcutaneous Methotrexate With an Autoinjector: Results of a Phase 2 Clinical Trial in Patients With Rheumatoid Arthritis Who Have Functional Limitations

BACKGROUND: A methotrexate autoinjector (MTXAI) was developed for self-administration of subcutaneous (SC) methotrexate by patients with rheumatoid arthritis (RA). The MTXAI circumvents the need for vials, needles, and syringes and may therefore improve dosing accuracy, handling risks, and patient a...

Descripción completa

Detalles Bibliográficos
Autores principales: Freundlich, Bruce, Kivitz, Alan, Jaffe, Jonathan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165470/
https://www.ncbi.nlm.nih.gov/pubmed/25036562
http://dx.doi.org/10.1097/RHU.0000000000000117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165470/
https://www.ncbi.nlm.nih.gov/pubmed/25036562
http://dx.doi.org/10.1097/RHU.0000000000000117

Ejemplares similares